Efficacy outcomes of CDK4/6 inhibitors in combination with endocrine therapy treatment in hormone receptor-positive/HER2-negative advanced breast cancer according to PAM50 intrinsic subtype: Primary results of SOLTI-1801 CDK-PREDICT studyPablo Tolosa, Eva Ciruelos, Tomás Pascual et al.|European Journal of Cancer|2025Cited by 10
Abstract P5-13-24: Efficacy of first line CDK4/6 inhibitors in HER2-low vs HER2-zero, hormone receptor positive, HER2 negative metastatic breast cancerRodrigo Sánchez-Bayona, Pablo Tolosa, Santiago Terán et al.|Cancer Research|2022Cited by 4
CD44v6 Drives Tumor Aggressiveness and Chemoresistance in Bladder CancerIris Lodewijk, Marta Dueñas, Daniel Castellano et al.|bioRxiv (Cold Spring Harbor Laboratory)|2025Cited by 0
Real-world second- and third-line progression-free survival after progression on first-line CDK4/6 inhibitors in HR+/HER2- metastatic breast cancer by PAM50 intrinsic subtype: the SOLTI-1801 CDK-PREDICT studyPablo Tolosa, Eva Ciruelos, Isabel García-Fructuoso et al.|Breast Cancer Research and Treatment|2026Cited by 0
CD44v6 is associated with tumor aggressiveness and chemoresistance in bladder cancerIris Lodewijk, Marta Dueñas, Carolina Rubio et al.|Scientific Reports|2026Cited by 0